The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Arcturus has made progress in cost-cutting and focusing on CF and OTC deficiency. Click here to find out the factors that ...

Moderna is preparing to test Health Secretary Robert F. Kennedy Jr.'s tougher vaccine policies with a combination flu-COVID ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

Smart mRNA drugs listen to the body, adjusting protein production based on disease-related signals by University of Osaka edited by Lisa Lock, reviewed by Robert Egan Editors' notes ...

mRNA vaccines work differently: The antigen is produced inside the body. The vaccine itself consists of a small piece of genetic code—messenger RNA (mRNA)—to which the immune system responds.